EUVIMEDEUVIMED entdecken
Crossref

Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL)

Charlotte O'Halloran, Yvonne Gilleece, Suki Leung, Veronica Canuto, Connor McAlpine, Sophie Ross iD, Claire Norcross, Stuart Gaffney, Nipur Siani, William Hickey iD, Adam Moore, Olivera Rajkovic-Hooley und 1 weitere

International Journal of STD & AIDS · 2024

DOI: 10.1177/09564624231215977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of STD & AIDS, 2024. Verfasst von Charlotte O'Halloran und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs (HIV), MSD (UK) Limited, London, UK. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Merck Sharp and Dohme UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK.

Methods

A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy.

Results

At baseline 83% of individuals were male, 45% aged ≥50 years, 65% white ethnicity. Median time since HIV diagnosis was 12 years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV-1HIV InfectionsPyridonesTriazolesAdultMiddle AgedHumansMaleFemaleRetrospective StudiesEngland

Stichwörter der Autor:innen

Antiretroviral therapyhuman immunodeficiency virus)otherviral disease

Substanzen

Anti-HIV AgentsdoravirinePyridonesTriazoles

Autor:innen und Institutionen

  • Medical Affairs (HIV), MSD (UK) Limited, London, UK.
  • HIV and Sexual Health, Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust, Brighton, UK.
  • St Stephen's Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • College London and Mortimer Market Centre, Centre for Clinical Research in Infection and Sexual Health University, London, UK.
  • Adelphi Real World (ARW), Bollington, UK.
  • Imperial College London, London, UK.

ORCID-Profile: Sophie Ross, William Hickey

Förderung

  • Merck Sharp and Dohme UK

Zitieren

APA

O'Halloran, C., Gilleece, Y., Leung, S., Canuto, V., McAlpine, C., Ross, S., Norcross, C., Gaffney, S., Siani, N., Hickey, W., Moore, A., Rajkovic-Hooley, O., & Milinkovic, A. (2024). Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL). International Journal of STD & AIDS. https://doi.org/10.1177/09564624231215977

Vancouver

O'Halloran C, Gilleece Y, Leung S, Canuto V, McAlpine C, Ross S, et al. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL). International Journal of STD & AIDS. 2024. doi:10.1177/09564624231215977

BibTeX
@article{OHalloran2024,
  author = {O'Halloran, Charlotte and Gilleece, Yvonne and Leung, Suki and Canuto, Veronica and McAlpine, Connor and Ross, Sophie and Norcross, Claire and Gaffney, Stuart and Siani, Nipur and Hickey, William and Moore, Adam and Rajkovic-Hooley, Olivera and Milinkovic, Ana},
  title = {Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL)},
  journal = {International Journal of STD & AIDS},
  year = {2024},
  doi = {10.1177/09564624231215977}
}
Kostenlos starten →